Participants with confirmed PDAC, undergoing staging evaluation for treatment planning.
Eastern Cooperative Oncology Group (ECOG) performance status ≤2:
Provided signed, written informed consent obtained prior to any study-related procedures.
Participants are required to have a ceCT scan of chest, abdomen and pelvis as per standard clinical practice and practice guidelines either 21 days or less prior to entry or planned within 21 days of \[¹⁸F\]FAPI-74 administration.
For women who are not postmenopausal (two years of amenorrhea) or surgically sterile (absence of ovaries and/or uterus): agreement to use medically accepted, highly effective methods of contraception (e.g., hormonal implants, combined oral contraceptives, vasectomized partner , during the trial intervention period.
You may not be if
Unequivocal evidence of metastases at the time of enrollment that would preclude surgery as a treatment option.
Known hypersensitivity to \[¹⁸F\]FAPI-74.
Administration of another investigational therapeutic or diagnostic product within 30 days prior to \[¹⁸F\]FAPI-74 administration.
Prior administration of a radiopharmaceutical within 10 half-lives of that product from the time of \[¹⁸F\]FAPI-74 administration.
Previous cancer diagnosis (except basal cell carcinoma of the skin or in situ carcinoma of the cervix/uterus). Participants treated with curative intent and disease-free for more than 5 years are permitted.
Hepatic function: T. bili \>1.5X ULN or alk phos, ALT, or AST \>5X ULN
Renal function: GFR \< 30 mL/min
Pregnant or breast feeding (a negative pregnancy test is required in women of childbearing potential)
Inability to undergo the PET/CT scanning procedure.
Inflammatory bowel disease (Crohn's disease or ulcerative colitis)
Sarcoidosis
Treatment, including chemotherapy, radiation or surgery for curative intent of PDAC.
Clareo Health | Using 18F-FAPI PET to Detect Metastatic Disease in Patients That Have Pancreatic Ductal Adenocarcinoma (PDAC)
